IPA / Sermorelin Blend
This blend pairs Ipamorelin with Sermorelin, the GHRH (1-29) analogue historically marketed in the US as Geref and approved for pediatric growth hormone deficiency.1 Sermorelin’s shorter half-life (vs CJC-1295) preserves the natural pulsatile architecture of GH release, which some clinicians prefer for first-time users or those with concerns about IGF-1 over-correction.
IPA / Sermorelin Blend at a glance
This blend pairs Ipamorelin with Sermorelin, the GHRH (1-29) analogue historically marketed in the US as Geref and approved for pediatric growth hormone deficiency.1 Sermorelin’s shorter half-life (vs CJC-1295) preserves the natural pulsatile architecture of GH release, which some clinicians prefer for first-time users or those with concerns about IGF-1 over-correction.
The result is a gentler protocol than CJC/Ipa — lower peak IGF-1 elevation, more physiologic pulse, and a smoother subjective profile. We often start new GH-peptide patients here before considering CJC-based blends.
Sermorelin binds GHRH receptor with native half-life; Ipamorelin adds the ghrelin arm without cortisol noise.1
Gentlest predictable entry into GH peptide therapy — easier to titrate, lower side-effect frequency.
What the research actually shows
IPA / Sermorelin Blend has been studied across multiple modalities. The summaries below cite peer-reviewed sources; individual response varies and is not guaranteed.
Preserves native pulsatile architecture more closely than long-half-life analogues.
GHRH-driven slow-wave sleep improvements reported consistently.2
Smaller, smoother IGF-1 rise than CJC/Ipa — useful for first-timers.
Improved subjective recovery layered onto the GH/IGF axis.
Among the best-tolerated GH peptide stacks.
Sermorelin’s prior FDA approval establishes a long safety baseline.3
Your consultation is complimentary. Our medical team reviews your goals, current treatments, and history before recommending anything.
How a IPA / Sermorelin Blend protocol typically runs at Luxbae
Dosing, cadence, and delivery method are tailored to you. The outline below describes the most common variant; your provider personalizes based on labs, current treatments, and goals.
Baseline IGF-1 and screening labs.
Nightly subcutaneous pre-sleep.
IGF-1 at 6–8 weeks; titration based on response.
Often a stepping stone to CJC-based protocols if more aggressive response is wanted.
Frequently sequenced alongside
- Standalone Sermorelin for solo GHRH.
- CJC / Ipamorelin if a stronger pulse is wanted.
- IGF-1 LR3 for direct IGF.
- Morpheus8 for collagen amplification.
Who it’s for — and who should avoid it
IPA / Sermorelin Blend eligibility is confirmed during your medical consultation; your full medical history must be disclosed.
- First-time GH peptide users.
- Patients wanting a physiologic pulse.
- Lower IGF-1 baseline.
- No malignancy history.
- Pregnancy or breastfeeding.
- Children and adolescents.
- Acute infection or autoimmune flare.
- Known peptide hypersensitivity.
- Active or recent malignancy.
- Untreated severe sleep apnea.
- Active proliferative retinopathy.
Possible side effects
Injection-site reactions, transient flushing, occasional headache, mild paresthesias.
FDA & regulatory note
Sermorelin was previously FDA-approved as Geref for pediatric GHD; current adult compounded use is investigational. Ipamorelin is not FDA-approved.
Dr. Ernst von Schwarz, MD, PhD
Professor Dr. Ernst von Schwarz — triple board-certified clinical and academic cardiologist, clinical professor of medicine at UCLA, and a three-decade pioneer in stem cell and regenerative medicine research — personally directs Luxbae’s peptide program. He has authored more than 150 peer-reviewed scientific papers and lectures internationally on cardiovascular and regenerative medicine. Every IPA / Sermorelin Blend protocol at Luxbae is prescribed and monitored under his direction.
Meet Dr. von SchwarzIPA / Sermorelin Blend FAQ
How is this different from CJC/Ipa?
Should I start here?
Can I upgrade later?
Why is Sermorelin special?
Will my labs change?
Cycle length?
Clinical References
Reviewed by Dr. Ernst von Schwarz and the Luxbae medical team. Statements on this page are educational and supported by the following peer-reviewed sources. Individual results vary.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clin Interv Aging. 2006;1(4):307-308. View
- Vitiello MV, et al. GHRH stimulates slow wave sleep in older adults. Sleep. 1997. View
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH(1-29)-NH2. J Clin Endocrinol Metab. 1997. View
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin. Eur J Endocrinol. 1998;139(5):552-561. View
Start your IPA / Sermorelin Blend protocol at Luxbae West Hollywood
Your consultation is complimentary. We’ll walk you through how IPA / Sermorelin Blend fits your goals, what labs (if any) we’d run, and how it would sequence with the rest of your aesthetic plan.